Alto Neuroscience (ANRO) Prepaid Assets (2023 - 2026)
Alto Neuroscience (ANRO) posted Prepaid Assets of $5.4 million for Q1 2026, up 334.68% sequentially from $1.2 million in Q4 2025, and up 23221.74% YoY from N/an in Q1 2025.
Analysis
Alto Neuroscience (ANRO) Prepaid Assets (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Prepaid Assets for 4 years, with the latest figure at $5.4 million in Q1 2026.
- Quarterly Prepaid Assets rose 23221.74% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (up 23221.74% YoY) and the FY2025 annual result came in at $1.2 million, up 11.37% from the prior year.
- Prepaid Assets climbed to $5.4 million in Q1 2026 per ANRO's latest filing, from $1.2 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $5.4 million in Q1 2026 and troughed at $23000.0 in Q1 2025.
- A 4-year average of $2.1 million and a median of $2.0 million in 2024 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2025 and 2026: Prepaid Assets slumped 99.05% in 2025, then surged 23221.74% in 2026.
- Over 4 years, Prepaid Assets stood at $2.8 million in 2023, then plunged by 61.03% to $1.1 million in 2024, then rose by 11.37% to $1.2 million in 2025, then surged by 334.68% to $5.4 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $5.4 million, $1.2 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Alto Neuroscience | 1.52 Bn | 1.52 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.59 Mn |
| Mar 31, 2026 | 5.36 Mn |
| Dec 31, 2025 | 1.23 Mn |
| Sep 30, 2025 | 1.63 Mn |
| Jun 30, 2025 | 2.26 Mn |
| Mar 31, 2025 | 2.77 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 1.83 Mn |
| Jun 30, 2024 | 2.29 Mn |
| Mar 31, 2024 | 2.42 Mn |
| Dec 31, 2023 | 2.84 Mn |